AR098414A1 - PIPERAZINAS DE PIRAZOLO SUSTITUIDO COMO INHIBIDORES DE CASEÍNA QUINASA 1 d/e - Google Patents
PIPERAZINAS DE PIRAZOLO SUSTITUIDO COMO INHIBIDORES DE CASEÍNA QUINASA 1 d/eInfo
- Publication number
- AR098414A1 AR098414A1 ARP140104277A ARP140104277A AR098414A1 AR 098414 A1 AR098414 A1 AR 098414A1 AR P140104277 A ARP140104277 A AR P140104277A AR P140104277 A ARP140104277 A AR P140104277A AR 098414 A1 AR098414 A1 AR 098414A1
- Authority
- AR
- Argentina
- Prior art keywords
- substituted
- independently selected
- nrara
- heterocyclyl
- alkyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/20—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/14—Ortho-condensed systems
- C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/20—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Sales de aquellos aceptables desde el punto de vista farmacéutico. Los compuestos inhiben la actividad de la proteína quinasa, lo cual los vuelve útiles como agentes antineoplásicos. Reivindicación 1: Un compuesto caracterizado por la fórmula (1), o una sal de este aceptable desde el punto de vista farmacéutico, en donde X se selecciona independientemente de O y NH; R¹ se selecciona independientemente de carbociclilo sustituido con 1 - 5 R⁵, y heterociclilo que comprende átomos de carbono y 1 a 3 heteroátomos seleccionados de N, NR⁴, O, S, y sustituidos con 1 - 5 R⁵; R² se selecciona independientemente de (i) alquilo opcionalmente sustituido con F, Cl, Br, ORᵇ, CN, NRᵃRᵃ, -C(=O)NRᵃRᵃ, C₂₋₆ alquenilo sustituido con 0 - 5 Rᵉ, C₂₋₆ alquinilo sustituido con 0 - 5 Rᵉ, carbociclilo sustituido con 1 - 8 R⁷ y heterociclilo que comprende átomos de carbono y 1 a 4 heteroátomos seleccionados de N, NR⁶, O, S, y sustituidos con 1 - 8 R⁷, (ii) cicloalquilo sustituido con 1 - 8 R⁷, y (iii) cicloheteroalquilo sustituido con 1 - 8 R⁷; R³ᵃ, R³ᵇ, R³ᶜ, R³ᵈ, R³ᵉ y R³ᶠ se seleccionan independientemente de H, CN, C₁₋₄ alquilo sustituido con 1 - 3 R⁸, -C(=O)ORᵇ, -C(=O)NRᵃRᵃ, -C(=O)Rᵇ, -NRᵃC(=O)Rᵇ, -NRᵃC(=O)ORᵇ, -(CH₂)ʳ-carbociclilo sustituido con 1 - 3 R⁸ y -(CH₂)ʳ-heterociclilo sustituido con 1 - 3 R⁸; de manera alternativa, R³ᵃ y R³ᵇ, o R³ᶜ y R³ᵈ o R³ᵉ y R³ᶠ, junto con el átomo de carbono al que están unidos, forman un anillo spiro carbocíclico o heterocíclico que comprende átomos de carbono y 1 a 4 heteroátomos seleccionados de N, O, S, cada uno sustituido con 1 - 5 R⁸; de manera alternativa, R³ᵃ y R³ᶜ, o R³ᵇ y R³ᵈ, juntos forman un anillo heterocíclico que comprende átomos de carbono y 1 a 4 heteroátomos seleccionados de N, O, S, y sustituidos con 1 - 5 R⁸; R⁴ se selecciona independientemente de H, C₁₋₄ alquilo sustituido con 0 - 3 Rᵉ, -(CH₂)ʳCN, -(CH₂)ʳORᵇ, (CH₂)ʳS(O)ₚRᶜ, -(CH₂)ʳC(=O)Rᵇ, -(CH₂)ʳNRᵃRᵃ, -(CH₂)ʳC(=O)NRᵃRᵃ, -(CH₂)ʳNRᵃC(=O)Rᵇ, -(CH₂)ʳNRᵃC(=O)ORᵇ, -(CH₂)ʳOC(=O)NRᵃRᵃ, -(CH₂)ʳNRᵃC(=O)NRᵃRᵃ, -(CH₂)ʳC(=O)ORᵇ, -(CH₂)ʳS(O)₂NRᵃRᵃ, -(CH₂)ʳNRᵃS(O)₂NRᵃRᵃ, -(CH₂)ʳNRᵃS(O)₂Rᶜ, (CH₂)ʳ-carbociclilo sustituido con 0 - 3 Rᵉ y -(CH₂)ʳ-heterociclilo sustituido con 0 - 3 Rᵉ; R⁵, en cada caso, se selecciona independientemente de H, C₁₋₄ alquilo sustituido con 0 - 3 Rᵉ, F, Cl, Br, =O, CN, NO₂, -ORᵇ, -(CH₂)ʳCN, -(CH₂)ʳORᵇ, (CH₂)ʳS(O)ₚRᶜ, -(CH₂)ʳC(=O)Rᵇ, -(CH₂)ʳNRᵃRᵃ, -(CH₂)ʳC(=O)NRᵃRᵃ, -(CH₂)ʳNRᵃC(=O)Rᵇ, -(CH₂)ʳNRᵃC(=O)ORᵇ, -(CH₂)ʳOC(=O)NRᵃRᵃ, -(CH₂)ʳNRᵃC(=O)NRᵃRᵃ, -(CH₂)ʳC(=O)ORᵇ, -(CH₂)ʳS(O)₂NRᵃRᵃ, -(CH₂)ʳNRᵃS(O)₂NRᵃRᵃ, -(CH₂)ʳNRᵃS(O)₂Rᶜ, (CH₂)ʳ-carbociclilo sustituido con 0 - 3 Rᵉ y -(CH₂)ʳ-heterociclilo sustituido con 0 - 3 Rᵉ; R⁶ se selecciona independientemente de H, -C(=O)Rᵇ, -CO(=O)Rᵇ, -S(O)ₚRᶜ, C₁₋₆ alquilo sustituido con 0 - 5 Rᵉ; -(CH₂)ʳ-C₃₋₆ carbociclilo sustituido con 0 - 5 Rᵉ y -(CH₂)ʳ-heterociclilo sustituido con 0 - 5 Rᵉ; R⁷, en cada caso, se selecciona independientemente de H, F, Cl, Br, =O, -(CRᵈRᵈ)ʳCN, NO₂, -(CRᵈRᵈ)ʳORᵇ, -S(O)ₚRᶜ, -C(=O)Rᵇ, -(CRᵈRᵈ)ʳNRᵃRᵃ, -(CRᵈRᵈ)ʳC(=O)NRᵃRᵃ, -NRᵃ(=O)Rᵇ, -NRᵃC(=O)ORᵇ, -OC(=O)NRᵃRᵃ, -NRᵃC(=O)NRᵃRᵃ, -(CRᵈRᵈ)ʳC(=O)ORᵇ, -S(O)₂NRᵃRᵃ, -NRᵃS(O)₂NRᵃRᵃ, -NRᵃS(O)₂Rᶜ, C₁₋₆ alquilo sustituido con 0 - 5 Rᵉ, -(CRᵈRᵈ)ʳ-C₃₋₆ carbociclilo sustituido con 0 - 5 Rᵉ y -(CRᵈRᵈ)ʳ-heterociclilo sustituido con 0 - 5 Rᵉ; R⁸, en cada caso, se selecciona independientemente de H, F, Cl, Br, CN, C₁₋₆ alquilo sustituido con 0 - 5 Rᵉ, C₂₋₆ alquenilo, C₂₋₆ alquinilo, -(CH₂)ʳ-C₃₋₆ cicloalquilo sustituido con 0 - 5 Rᵉ, -(CH₂)ʳ-arilo sustituido con 0 - 5 Rᵉ, -(CH₂)ʳ-heterociclilo sustituido con 0 - 5 Rᵉ, CO₂H, -(CH₂)ʳORᵇ y -(CH₂)ʳNRᵃRᵃ; Rᵃ, en cada caso, se selecciona independientemente de H, CN, C₁₋₆ alquilo sustituido con 0 - 5 Rᵉ, C₂₋₆ alquenilo sustituido con 0 - 5 Rᵉ, C₂₋₆ alquinilo sustituido con 0 - 5 Rᵉ, -(CH₂)ʳ-C₃₋₁₀ carbociclilo sustituido con 0 - 5 Rᵉ y -(CH₂)ʳ-heterociclilo sustituido con 0 - 5 Rᵉ; o Rᵃ y Rᵃ, junto con el átomo de nitrógeno al que están unidos, forman un anillo heterocíclico sustituido con 0 - 5 Rᵉ; Rᵇ, en cada caso, se selecciona independientemente de H, C₁₋₆ alquilo sustituido con 0 - 5 Rᵉ, C₂₋₆ alquenilo sustituido con 0 - 5 Rᵉ, C₂₋₆ alquinilo sustituido con 0 - 5 Rᵉ, -(CH₂)ʳ-C₃₋₁₀ carbociclilo sustituido con 0 - 5 Rᵉ y -(CH₂)ʳ-heterociclilo sustituido con 0 - 5 Rᵉ; Rᶜ, en cada caso, se selecciona independientemente de C₁₋₆ alquilo sustituido con 0 - 5 Rᵉ, C₂₋₆ alquenilo sustituido con 0 - 5 Rᵉ, C₂₋₆ alquinilo sustituido con 0 - 5 Rᵉ, C₃₋₆ carbociclilo y heterociclilo; Rᵈ, en cada caso, se selecciona independientemente de H y C₁₋₄ alquilo sustituido con 0 - 5 Rᵉ; Rᵉ, en cada caso, se selecciona independientemente de F, Cl, Br, CN, NO₂, =O, C₁₋₆ alquilo sustituido con 0 - 5 Rᶠ, C₂₋₆ alquenilo, C₂₋₆ alquinilo, -(CH₂)ʳ-C₃₋₆ cicloalquilo, -(CH₂)ʳ-arilo, -(CH₂)ʳ-heterociclilo, CO₂H, -(CH₂)ʳORᶠ, SRᶠ, y -(CH₂)ʳNRᶠRᶠ; Rᶠ, en cada caso, se selecciona independientemente de H, C₁₋₅ alquilo, opcionalmente sustituido con F, Cl, Br, C₃₋₆ cicloalquilo y fenilo, o Rᶠ y Rᶠ junto con el átomo de nitrógeno al que están unidos, forman un anillo heterocíclico opcionalmente sustituido con C₁₋₄ alquilo; p, en cada caso, se selecciona independientemente de 0, 1 y 2; y r, en cada caso, se selecciona independientemente de 0, 1, 2, 3 y 4.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361904116P | 2013-11-14 | 2013-11-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR098414A1 true AR098414A1 (es) | 2016-05-26 |
Family
ID=51952052
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP140104277A AR098414A1 (es) | 2013-11-14 | 2014-11-13 | PIPERAZINAS DE PIRAZOLO SUSTITUIDO COMO INHIBIDORES DE CASEÍNA QUINASA 1 d/e |
Country Status (9)
Country | Link |
---|---|
US (3) | US9598423B2 (es) |
EP (2) | EP3068784B1 (es) |
JP (2) | JP6494624B2 (es) |
CN (2) | CN105916856B (es) |
AR (1) | AR098414A1 (es) |
ES (2) | ES2718218T3 (es) |
TW (1) | TW201605859A (es) |
UY (1) | UY35834A (es) |
WO (2) | WO2015073767A1 (es) |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR098414A1 (es) | 2013-11-14 | 2016-05-26 | Bristol Myers Squibb Co | PIPERAZINAS DE PIRAZOLO SUSTITUIDO COMO INHIBIDORES DE CASEÍNA QUINASA 1 d/e |
US10189843B2 (en) | 2014-02-27 | 2019-01-29 | The University Of Tokyo | Fused pyrazole derivative having autotaxin inhibitory activity |
MA41338B1 (fr) * | 2015-01-16 | 2019-07-31 | Hoffmann La Roche | Composés de pyrazine pour le traitement de maladies infectieuses |
WO2017156071A1 (en) | 2016-03-09 | 2017-09-14 | Blade Therapeutics, Inc. | Cyclic keto-amide compounds as calpain modulators and methods of production and use thereof |
CN109153682B (zh) * | 2016-05-20 | 2021-05-25 | 豪夫迈·罗氏有限公司 | 用于治疗感染性疾病的具有氧、硫和氮连接基的新的吡嗪化合物 |
EP3481835A4 (en) | 2016-07-05 | 2020-02-26 | Blade Therapeutics, Inc. | CALPAIN MODULATORS AND THEIR THERAPEUTIC USES |
CN109476668B (zh) * | 2016-07-14 | 2022-03-22 | 豪夫迈·罗氏有限公司 | 用于治疗感染性疾病的6,7-二氢-4H-吡唑并[1,5-a]吡嗪和6,7-二氢-4H-三唑并[1,5-a]吡嗪化合物 |
CN110023304A (zh) * | 2016-09-28 | 2019-07-16 | 布莱德治疗公司 | 钙蛋白酶调节剂及其治疗用途 |
TWI782056B (zh) * | 2017-07-14 | 2022-11-01 | 日商鹽野義製藥股份有限公司 | 具有mgat2抑制活性的縮合環衍生物 |
KR20200032702A (ko) * | 2017-07-27 | 2020-03-26 | 지앙수 헨그루이 메디슨 컴퍼니 리미티드 | 피페라진 헤테로아릴 유도체, 그 제조 방법 및 의약에서 이의 용도 |
UY37861A (es) | 2017-08-28 | 2019-03-29 | Enanta Pharm Inc | Agentes antivirales contra la hepatitis b |
EP3681885B1 (en) | 2017-09-15 | 2024-02-28 | Forma Therapeutics, Inc. | Tetrahydro-imidazo quinoline compositions as cbp/p300 inhibitors |
JP7212693B2 (ja) | 2017-11-01 | 2023-01-25 | ブリストル-マイヤーズ スクイブ カンパニー | ファルネソイドx受容体モジュレーターとしての架橋二環化合物 |
US11058678B2 (en) | 2018-01-22 | 2021-07-13 | Enanta Pharmaceuticals, Inc. | Substituted heterocycles as antiviral agents |
US10729688B2 (en) * | 2018-03-29 | 2020-08-04 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
WO2019228252A1 (zh) * | 2018-06-01 | 2019-12-05 | 杭州阿诺生物医药科技有限公司 | 一种高活性csf1r抑制剂化合物 |
MX2023013508A (es) | 2018-06-29 | 2023-12-13 | Forma Therapeutics Inc | Inhibicion de la proteina de union a creb (cbp). |
CN112955142A (zh) | 2018-09-21 | 2021-06-11 | 英安塔制药有限公司 | 官能化杂环化合物作为抗病毒剂 |
BR112021009854A2 (pt) | 2018-11-21 | 2021-08-17 | Enanta Pharmaceuticals, Inc. | heterociclos funcionalizados como agentes antivirais |
AU2020210998A1 (en) * | 2019-01-25 | 2021-09-16 | Jiangsu Hengrui Medicine Co., Ltd. | Crystal form of 1,2,3-triazolo(1,5-a)pyrazines derivative and preparation method for crystal form |
CN111484497B (zh) * | 2019-01-25 | 2021-07-02 | 江苏恒瑞医药股份有限公司 | 咪唑并[1,5-a]吡嗪类衍生物的可药用盐、晶型及其制备方法 |
CN111484498B (zh) * | 2019-01-25 | 2021-05-14 | 江苏恒瑞医药股份有限公司 | 咪唑并[1,5-a]吡嗪类化合物的晶型及其制备方法 |
WO2020247444A1 (en) | 2019-06-03 | 2020-12-10 | Enanta Pharmaceuticals, Inc, | Hepatitis b antiviral agents |
WO2020247575A1 (en) | 2019-06-04 | 2020-12-10 | Enanta Pharmaceuticals, Inc. | Hepatitis b antiviral agents |
US11760755B2 (en) | 2019-06-04 | 2023-09-19 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
WO2021007488A1 (en) | 2019-07-11 | 2021-01-14 | Enanta Pharmaceuticals, Inc. | Substituted heterocycles as antiviral agents |
WO2021055425A2 (en) | 2019-09-17 | 2021-03-25 | Enanta Pharmaceuticals, Inc. | Functionalized heterocycles as antiviral agents |
WO2021188414A1 (en) | 2020-03-16 | 2021-09-23 | Enanta Pharmaceuticals, Inc. | Functionalized heterocyclic compounds as antiviral agents |
CN114057745A (zh) * | 2020-07-29 | 2022-02-18 | 江苏恒瑞医药股份有限公司 | 一种三氮唑并[1,5-a]吡嗪制备方法及其应用 |
MX2023003165A (es) * | 2020-09-17 | 2023-06-07 | Janssen Pharmaceutica Nv | Moduladores de la caseína cinasa 1 delta. |
US11801243B2 (en) | 2020-09-23 | 2023-10-31 | Forma Therapeutics, Inc. | Bromodomain inhibitors for androgen receptor-driven cancers |
US11795168B2 (en) | 2020-09-23 | 2023-10-24 | Forma Therapeutics, Inc. | Inhibiting cyclic amp-responsive element-binding protein (CREB) binding protein (CBP) |
TW202245772A (zh) * | 2021-02-04 | 2022-12-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 一種衣殼蛋白抑制劑的醫藥組成物及其製備方法 |
WO2023147015A1 (en) * | 2022-01-27 | 2023-08-03 | The Broad Institute, Inc. | Substituted heterocyclic csnk1 inhibitors |
WO2023243616A1 (ja) * | 2022-06-13 | 2023-12-21 | 塩野義製薬株式会社 | ジヒドロピリジノン誘導体またはその溶媒和物の結晶 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MXPA04002243A (es) * | 2001-09-19 | 2004-06-29 | Aventis Pharma Sa | Compuestos quimicos. |
US7402672B2 (en) * | 2003-12-11 | 2008-07-22 | Aventis Pharmaceuticals Inc. | Substituted 1H-pyrrolo[3,2-b, 3,2-c, and 2,3-c]pyridine-2-carboxamides and related analogs as inhibitors of casein kinase lepsilon |
US20050222171A1 (en) * | 2004-01-22 | 2005-10-06 | Guido Bold | Organic compounds |
US20070155738A1 (en) | 2005-05-20 | 2007-07-05 | Alantos Pharmaceuticals, Inc. | Heterobicyclic metalloprotease inhibitors |
CN101417999A (zh) | 2007-10-25 | 2009-04-29 | 上海恒瑞医药有限公司 | 哌嗪类衍生物,其制备方法及其在医药上的应用 |
EP2085398A1 (en) | 2008-02-01 | 2009-08-05 | Merz Pharma GmbH & Co. KGaA | Pyrazolopyrimidines, a process for their preparation and their use as medicine |
US8853125B2 (en) | 2008-09-24 | 2014-10-07 | Basf Se | Pyrazole compounds for controlling invertebrate pests |
US8703778B2 (en) | 2008-09-26 | 2014-04-22 | Intellikine Llc | Heterocyclic kinase inhibitors |
WO2010059836A1 (en) | 2008-11-20 | 2010-05-27 | Decode Genetics Ehf | Substituted aza-bridged bicyclics for cardiovascular and cns disease |
TW201035102A (en) | 2009-03-04 | 2010-10-01 | Gruenethal Gmbh | Sulfonylated tetrahydroazolopyrazines and their use as medicinal products |
FR2960876B1 (fr) * | 2010-06-03 | 2012-07-27 | Sanofi Aventis | Derives de 3,4-dihydropyrrolo[1,2-a]pyrazine-2,8(1h)-dicarboxamide leur preparation et leur application en therapeutique. |
CN102372716A (zh) | 2010-08-09 | 2012-03-14 | 江苏恒瑞医药股份有限公司 | 酞嗪酮类衍生物、其制备方法及其在医药上的应用 |
EP2680852A1 (en) | 2011-03-02 | 2014-01-08 | Lead Discovery Center GmbH | Pharmaceutically active disubstituted triazine derivatives |
AR098414A1 (es) | 2013-11-14 | 2016-05-26 | Bristol Myers Squibb Co | PIPERAZINAS DE PIRAZOLO SUSTITUIDO COMO INHIBIDORES DE CASEÍNA QUINASA 1 d/e |
-
2014
- 2014-11-13 AR ARP140104277A patent/AR098414A1/es unknown
- 2014-11-13 UY UY0001035834A patent/UY35834A/es unknown
- 2014-11-13 TW TW103139448A patent/TW201605859A/zh unknown
- 2014-11-14 WO PCT/US2014/065599 patent/WO2015073767A1/en active Application Filing
- 2014-11-14 ES ES14802796T patent/ES2718218T3/es active Active
- 2014-11-14 US US15/034,217 patent/US9598423B2/en active Active
- 2014-11-14 WO PCT/US2014/065594 patent/WO2015073763A1/en active Application Filing
- 2014-11-14 JP JP2016531646A patent/JP6494624B2/ja active Active
- 2014-11-14 JP JP2016531020A patent/JP6494622B2/ja active Active
- 2014-11-14 EP EP14802796.4A patent/EP3068784B1/en active Active
- 2014-11-14 CN CN201480073199.9A patent/CN105916856B/zh active Active
- 2014-11-14 ES ES14806145T patent/ES2744636T3/es active Active
- 2014-11-14 CN CN201480073088.8A patent/CN105916855B/zh active Active
- 2014-11-14 US US14/541,343 patent/US9273058B2/en active Active
- 2014-11-14 EP EP14806145.0A patent/EP3068785B1/en active Active
-
2016
- 2016-01-13 US US14/994,346 patent/US20160122358A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20160311824A1 (en) | 2016-10-27 |
US20160122358A1 (en) | 2016-05-05 |
WO2015073763A1 (en) | 2015-05-21 |
EP3068784B1 (en) | 2019-02-20 |
CN105916856B (zh) | 2018-09-25 |
JP6494624B2 (ja) | 2019-04-03 |
CN105916856A (zh) | 2016-08-31 |
US20150133428A1 (en) | 2015-05-14 |
JP2016537366A (ja) | 2016-12-01 |
CN105916855B (zh) | 2019-03-15 |
EP3068785B1 (en) | 2019-06-26 |
ES2718218T3 (es) | 2019-06-28 |
UY35834A (es) | 2015-05-29 |
CN105916855A (zh) | 2016-08-31 |
TW201605859A (zh) | 2016-02-16 |
JP6494622B2 (ja) | 2019-04-03 |
US9273058B2 (en) | 2016-03-01 |
EP3068784A1 (en) | 2016-09-21 |
EP3068785A1 (en) | 2016-09-21 |
JP2016537369A (ja) | 2016-12-01 |
US9598423B2 (en) | 2017-03-21 |
ES2744636T3 (es) | 2020-02-25 |
WO2015073767A1 (en) | 2015-05-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR098414A1 (es) | PIPERAZINAS DE PIRAZOLO SUSTITUIDO COMO INHIBIDORES DE CASEÍNA QUINASA 1 d/e | |
AR092349A1 (es) | Imidazotriazincarbonitrilos utiles como inhibidores de quinasa | |
AR106948A1 (es) | Agonistas del receptor de apelina y método de uso | |
AR096788A1 (es) | Compuestos tricíclicos de carboxamida como inhibidores potentes de rock | |
AR107061A1 (es) | Heteroarilhidroxipirimidinonas como agonistas del receptor de apj | |
AR099379A1 (es) | Compuestos tricíclicos como agentes antineoplásicos | |
AR104884A1 (es) | Compuestos de 4-hidroxi-3-(heteroaril)piridin-2-ona como agonistas de apj | |
AR107973A1 (es) | 6-hidroxi-4-oxo-1,4-dihidropirimidin-5-carboxamidas como agonista de apj | |
AR096450A1 (es) | Compuestos para la modulación de quinasas, y sus indicaciones | |
AR108388A2 (es) | Compuestos de oxazol sustituidos con indazol como inhibidores de pi3-quinasas | |
AR108838A1 (es) | Ácidos de carbamoiloximetil triazol ciclohexilo como antagonistas de lpa | |
AR110405A1 (es) | Compuestos | |
AR111419A1 (es) | Compuestos fusionados de indazol piridona como antivirales | |
AR100807A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
AR100809A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
AR094929A1 (es) | Derivados de fenilpirazol como inhibidores potentes de rock1 y rock2 | |
AR103990A1 (es) | Ureas cíclicas como inhibidoras de rock | |
AR091981A1 (es) | Dihidropiridona p1 como inhibidores del factor xia | |
AR094299A1 (es) | Derivados de ftalazin-1(2h)-ona sustituidos | |
AR100808A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
AR103742A1 (es) | Derivados de trifluorometilpropanamida | |
AR097866A1 (es) | Derivados de 4-azaindol | |
AR107321A1 (es) | Compuestos antiproliferativos, y sus composiciones farmacéuticas y usos | |
AR088320A1 (es) | Derivados de isoindolinona y pirrolopiridinona como inhibidores de akt | |
AR090557A1 (es) | DERIVADOS IMIDAZOLICOS AGONISTAS ADRENERGICOS a2 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |